Method and reagent for quantitative determination of 1,5-anhydroglucitol

ABSTRACT

The present invention provides a simple method for the determination of a specific component, e.g. 1,5-anhydroglucitol (1,5-AG) in a sample containing glucose, and a reagent and a reagent kit useful in the method. In one embodiment, a method for the determination of 1,5-AG is provided which comprises contacting the sample with an enzyme system which converts glucose into fructose-1,6-diphosphate and converts 1,5-AG into 1,5-AG-6-phosphate to form 1,5-AG-6-phosphate, dehydrogenating 1,5-AG-6-phosphate in the sample by the action of 1,5-AG-6-phosphate dehydrogenase in the presence of an oxidized coenzyme, and measuring the amount of the reduced coenzyme formed by the dehydrogenation reaction. A reagent and a reagent kit useful in this method are also provided.

This application is a division of application Ser. No. 09/456,998 filedDec. 7, 1999.

BACKGROUND OF THE INVENTION

The present invention relates to a method for the quantitativedetermination of a specific component, e.g., 1,5-anhydroglucitol(hereinafter referred to as 1,5-AG) in a sample by utilizing an enzymereaction. The method involves pretreatment which converts glucose in thesample into another substance. The invention also relates to a reagentand a reagent kit useful in the method.

Biological samples contain glucose, sometimes at very highconcentrations compared with analytes, which may reduce the accuracy ofassay results for analytes. In such cases, prior to the determination ofanalytes, glucose in samples is removed therefrom or converted intosubstances which do not interfere with the determination of analytes.

Previous methods for removing glucose from samples include methods inwhich glucose is separated by ion exchange column chromatography(Japanese Published Unexamined Patent Applications Nos. 185307/88 and6756/89). Previous methods for converting glucose in samples into othersubstances include (1) a method in which glucose is converted intoglucose-6-phosphate by a reaction utilizing the action of aphosphorylated enzyme such as glucokinase or hexokinase in the presenceof adenosine triphosphate (ATP), and (2) a method in which glucose isconverted into gluconolactone by a reaction utilizing the action ofoxidase such as glucose oxidase, pyranose oxidase or sorbose oxidase inthe presence of oxygen.

Further, various improvements have been made to these methods for theconversion of glucose. For example, modifications of the above method(1) using a phosphorylated enzyme include the following: a method inwhich glucose is converted into fructose-1,6-diphosphate by the actionof phosphohexose isomerase and 6-phosphofructokinase in order to preventthe reconversion of glucose-6-phosphate into glucose by equilibriumreaction (Japanese Published Unexamined Patent Application No.76397/93); methods using glucose-6-phosphate dehydrogenase in thepresence of oxidized coenzymes (Japanese Published Unexamined PatentApplications Nos. 320998/89, 27299/91 and 237794/94); and a method usingpyruvate kinase in the presence of adenosine diphosphate (ADP) toprevent the change in concentration of ATP, which decreases in theelimination of glucose, and to keep the ATP concentration constant(Japanese Published Unexamined Patent Application No. 104298/90).Modifications of the above method (2) using oxidase include a method inwhich a reaction using glucose oxidase is carried out and then theformed hydrogen peroxide is eliminated by the action of catalase(Japanese Published Unexamined Patent Application No. 185397/88).

However, the above methods suffer from the defect that enzyme reactionsystems for the determination of analytes may be affected by thesubstances used for the conversion of glucose into other substances andthe substances formed in the conversion system as well as theirconcentration. For example, when glucose is eliminated by the use ofglucokinase or hexokinase (Japanese Published Unexamined PatentApplication No. 76397/93), ADP is unfavorably formed in largequantities. Particularly, when a sufficient amount of ATP is supplied inorder to completely eliminate glucose, ADP is formed at a concentrationwhich is two times higher than that of glucose. The influence of ADP atsuch concentration on the reaction systems is not negligible.

1,5-AG is present in biological fluids such as cerebrospinal fluid,blood plasma, serum and urine. The level of 1,5-AG in blood plasmadecreases in patients of certain diseases, especially diabetes, and thus1,5-AG is useful as a diagnostic marker for diabetes. However, thedetermination of 1,5-AG is very difficult because of the closesimilarity in structure between 1,5-AG and glucose and the smallquantity of 1,5-AG compared with glucose.

It is known that enzymes such as sorbose oxidase, pyranose oxidase,hexokinase, glucokinase and ADP-dependent hexokinase act on 1,5-AG, butthese enzymes react also with sugars such as glucose which coexist with1,5-AG. Therefore, some measures must be taken for removing oreliminating these sugars such as glucose.

Some methods comprising the step of elimination of glucose are known forthe 1,5-AG determination in which 1,5-AG is oxidized using the catalyticaction of pyranose oxidase or sorbose oxidase and the formed hydrogenperoxide is determined.

Examples of such methods are: (1) methods for 1,5-AG determination whichcomprise separating glucose in a sample by ion column chromatography,contacting the sample with pyranose oxidase, and determining the formedhydrogen peroxide (Japanese Published Unexamined Patent ApplicationsNos. 185307/88 and 6756/89); (2) methods for 1,5-AG determination whichcomprise converting glucose in a sample into a compound which does notreact with pyranose oxidase by the action of glucokinase or hexokinaseand glucose-6-phosphate dehydrogenase, contacting the sample withpyranose oxidase, and determining the formed hydrogen peroxide (JapanesePublished Unexamined Patent Applications Nos. 320998/89 and 27299/91);(3) a method for 1,5-AG determination which comprises converting glucosein a sample into a compound which does not react with pyranose oxidaseby the action of glucokinase and pyruvate kinase, contacting the samplewith pyranose oxidase, and determining the formed hydrogen peroxide(Japanese Published Unexamined Patent Application No. 104298/90); and(4) a method for 1,5-AG determination which comprises converting glucosein a sample into a compound which does not react with pyranose oxidaseby the action of hexokinase, phosphohexose isomerase and6-phosphofructokinase, contacting the sample with sorbose oxidase orpyranose oxidase, and determining the formed hydrogen peroxide (JapanesePublished Unexamined Patent Application No. 76397/93).

However, the above methods (1) using columns are disadvantageous becauseof their complicatedness in operation, and the above methods (2)-(4)have the disadvantage that hexokinase and glucokinase used in theirglucose elimination systems act also on 1,5-AG to form1,5-AG-6-phosphate, which reduces the accuracy of the assays for 1,5-AG.

Further, some methods comprising the step of elimination of glucose areknown for the 1,5-AG determination in which 1,5-AG is phosphorylatedusing the catalytic action of hexokinase, glucokinase or ADP-dependenthexokinase and the formed substance is determined.

Examples of such methods are: (5) a method for 1,5-AG determinationwhich comprises separating glucose in a sample by ion columnchromatography, contacting the sample with hexokinase or glucokinase,and determining the formed ADP (Japanese Published Unexamined PatentApplication No. 107796/96); and (6) a method for 1,5-AG determinationwhich comprises converting glucose in a sample into a compound whichdoes not react with ADP-dependent hexokinase by the action of (a)glucose oxidase, or glucose oxidase and catalase, (b) glucosedehydrogenase, or (c) hexokinase or glucokinase, contacting the samplewith ADP-dependent hexokinase and 1,5-AG-6-phosphate dehydrogenase, anddetermining the formed reduced nicotinamide adenine dinucleotide(phosphate) [NAD(P)H] (Japanese Published Unexamined Patent AppllicationNo. 191998/98).

However, these methods suffer from the following disadvantages. Method(5) requires complicated operations. In method (6), in the case of (a)using glucose oxidase, oxygen supply is a rate-limiting step whenglucose is present in a sample at a high concentration; in the case of(b) using glucose dehydrogenase, a system for eliminating NAD(P)H formedfrom glucose is required; and in the case of (c) using hexokinase orglucokinase, fractional determination can not be carried out because1,5-AG-6-phosphate dehydrogenase acts on glucose-6-phosphate formed fromglucose, and when the method is applied to samples containing a largequantity of glucose such as those from diabetes patients, ADP formed inthe reaction system in a large quantity has an unfavorable effect on theaccuracy of the assay for 1,5-AG.

Under the circumstances, an object of the present invention is toprovide a simple method for the determination of a specific component,e.g. 1,5-AG, in a sample containing glucose, a method for substantiallycompletely eliminating glucose in a sample in the determination of aspecific component in the sample, and a reagent and a kit useful in themethods.

SUMMARY OF THE INVENTION

The present invention relates to a method for determining 1,5-AG in asample containing glucose, which comprises contacting the sample with anenzyme system which converts glucose into fructose-1,6-diphosphate andconverts 1,5-AG into 1,5-AG-6-phosphate to form 1,5-AG-6-phosphate,dehydrogenating 1,5-AG-6-phosphate in the sample by the action of1,5-AG-6-phosphate dehydrogenase in the presence of an oxidizedcoenzyme, and measuring the amount of the reduced coenzyme formed by thedehydrogenation reaction.

The present invention also relates to a reagent for the determination of1,5-AG, comprising (a) nucleosidediphosphate (hereinafter referred to asNDP), nucleoside triphosphate (hereinafter referred to as NTP),NDP-dependent hexokinase, phosphohexose isomerase,6-phosphofructokinase, an oxidized coenzyme and 1,5-AG-6-phosphatedehydrogenase, or (b) one member selected from the group consisting ofNTP-dependent hexokinase and NTP-dependent glucokinase, NTP,phosphohexose isomerase, 6-phosphofructokinase, an oxidized coenzyme and1,5-AG-6-phosphate dehydrogenase.

The present invention further relates to a reagent kit for thedetermination of 1,5-AG, comprising (a) a reagent comprising NDP, NTP,NDP-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase, or (b) a reagent comprising one member selectedfrom the group consisting of NTP-dependent hexokinase and NTP-dependentglucokinase, NTP, phosphohexose isomerase and 6-phosphofructokinase, anda reagent comprising an oxidized coenzyme and 1,5-AG-6-phosphatedehydrogenase.

The present invention further relates to a method for eliminatingglucose in a sample, which comprises converting glucose in the sampleinto fructose-1,6-diphosphate by the action of NDP-dependent hexokinase,phosphohexose isomerase and 6-phosphofructokinase in the presence of NDPand NTP.

The present invention further relates to a reagent for the eliminationof glucose, comprising NDP, NTP, NDP-dependent hexokinase, phosphohexoseisomerase and 6-phosphofructokinase.

The present invention further relates to a method for determining ananalyte in a sample containing glucose, which comprises convertingglucose in the sample into fructose-1,6-diphosphate by the action ofNDP-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase in the presence of NDP and NTP, and determiningthe analyte in the sample by using a chemical or enzymatic reaction.

The present invention further relates to a reagent for the determinationof an analyte, comprising NDP, NTP, NDP-dependent hexokinase,phosphohexose isomerase, 6-phosphofructokinase, and an enzyme acting onthe analyte or a substance reacting with the analyte.

The present invention further relates to a reagent kit for thedetermination of an analyte, comprising a reagent comprising NDP, NTP,NDP-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase, and a reagent comprising an enzyme acting on theanalyte or a substance reacting with the analyte.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a calibration curve for 1,5-AG. 1,5-AG on the abscissarefers to 1,5-anhydroglucitol and mAbs on the ordinate refers tomilli-absorbance.

FIG. 2 is a graph showing the correlation between the 1,5-AGconcentration determined by the method of the invention (a: ordinate)and the 1,5-AG concentration determined by the control method (Lana1,5-AG Auto) (b: abscissa).

FIG. 3 shows a calibration curve for 1,5-AG.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is applicable to assays of any samples which maycontain glucose, for example, biological samples such as blood, plasma,serum and urine.

In accordance with the present invention, elimination of glucose insamples is carried out by converting glucose intofructose-1,6-diphosphate according to the following reaction formula.

Conversion of glucose into glucose-6-phosphate alone is not sufficientfor eliminating glucose because this conversion reaction is reversibleand will allow the formed glucose-6-phosphate to be reconverted intoglucose. In the above reaction system, glucose in a sample can becompletely eliminated by converting glucose intofructose-1,6-diphosphate so as to prevent the reconversion into glucose.

The enzyme system which converts glucose into fructose-1,6-diphosphatecomprises an enzyme system for forming glucose-6-phosphate from glucose(hereinafter referred to as enzyme system 1), an enzyme system forforming fructose-6-phosphate from glucose-6-phosphate (hereinafterreferred to as enzyme system 2), and an enzyme system for formingfructose-1,6-diphosphate from fructose-6-phosphate (hereinafter referredto as enzyme system 3).

Enzyme system 1 includes the following two systems: (a) in which theenzyme is NDP-dependent hexokinase and the coenzyme is NDP, which isconverted into NMP, and (b) in which the enzyme is NTP-dependenthexokinase or NTP-dependent glucokinase and the coenzyme is NTP, whichis converted into NDP. In enzyme system 2, the enzyme is phosphohexoseisomerase. In enzyme system 3, the enzyme is 6-phosphofructokinase andthe coenzyme is NTP, which is converted into NDP.

When enzyme system 1 is the system in which the enzyme is NDP-dependenthexokinase and the coenzyme is NDP which is converted into NMP, NDP isconsumed according to the glucose concentration, but an equal amount ofNDP to that consumed is formed from NTP by the action of6-phosphofructokinase, whereby the NDP concentration can be keptconstant. Thus, the NDP concentration in the reaction system is notsubject to variation due to the change in glucose concentration in asample.

In the practice of the present invention, elimination of glucose iscarried out by adding to a sample containing glucose (a) NDP, NTP,NDP-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase, or (b) one member selected from the groupconsisting of NTP-dependent hexokinase and NTP-dependent glucokinase,NTP, phosphohexose isomerase and 6-phosphofructokinase, and subjectingthe mixture to reaction at 10-50° C. for 1-30 minutes, preferably 2-10minutes, if necessary in the presence of an aqueous medium, an enzymeactivity moderator, an activator, a preservative, a stabilizer, asurfactant, a chromogen, an electron acceptor, a tetrazolium salt, anadditional enzyme, a substrate for said enzyme, a coenzyme, etc.

The concentration of NDP-dependent hexokinase, NTP-dependent hexokinaseand NTP-dependent glucokinase is preferably 0.1-100 U/ml, morepreferably 0.5-50 U/ml, and most preferably 1-50 U/ml.

The concentration of phosphohexose isomerase is preferably 0.1-100 U/ml,more preferably 0.5-50 U/ml, and most preferably 5-50 U/ml.

The concentration of 6-phosphofructokinase is preferably 0. 1-100 U/ml,more preferably 0.5-50 U/ml, and most preferably 5-50 U/ml.

All of the above enzymes are commercially available and easilyacquirable. For example, NDP-dependent hexokinase enzymes derived fromThermococcus litoralis and Pyrococcus furiosus are easily acquirablefrom Asahi Chemical Industry Co., Ltd., and NTP-dependent hexokinaseenzymes derived from microorganisms of the genera. Saccharomyces,Kluyveromyces, Bacillus, etc. are easily acquirable from Oriental YeastCo., Ltd., Toyobo Co., Ltd., Boehringer Mannheim GmbH, Asahi ChemicalIndustry Co., Ltd., etc. NTP-dependent glucokinase enzymes derived frommicroorganisms of the genera Zymomonas, Bacillus, etc. are easilyacquirable from Unitika Ltd., etc. Phosphohexose isomerase derived fromBacillus stearothermophilus is available from Unitika Ltd. and6-phosphofructokinase derived from Bacillus stearothermophilus is alsoavailable from Unitika Ltd.

The concentration of NDP and NTP is preferably 0.01-100 mM, morepreferably 0.1-50 mM, and most preferably 1-10 mM. Examples of theactivators include inorganic salts such as magnesium sulfate andmagnesium chloride. The concentration of the inorganic salt ispreferably 0.001-10 mg/ml, more preferably 0.01-5 mg/ml, and mostpreferably 0.1-2 mg/ml.

After glucose in a sample is eliminated by the above-described reaction,a reaction is carried out in the presence of a reagent necessary for thedetermination of an analyte in the sample and the amount of a substanceformed or consumed by the reaction is measured, whereby the analyte canbe determined. There is no specific restriction as to the reagentnecessary for the determination, but it is appropriate to use a reagentcontaining an enzyme acting on the analyte or a substance reacting withthe analyte, preferably, a reagent containing an enzyme acting on theanalyte.

In cases where the enzyme acting on the analyte acts also on glucose andthe reaction catalyzed by the enzyme is subject to the influence of theNDP concentration, it is preferred to eliminate glucose by using system(a) above in which the enzyme is NDP-dependent hexokinase and thecoenzyme is NDP which is converted into NMP.

Examples of such enzymes include nucleotidase, 6-phosphogluconatedehydrogenase, NDP pyrophosphatase, NDP glucose pyrophosphorylase,NDP-dependent hexokinase and 1,5-AG-6-phosphate dehydrogenase.

When the above enzyme system for glucose elimination is applied to thedetermination of 1,5-AG, the enzyme system simultaneously catalyzes theconversion of 1,5-AG into 1,5-AG-6-phosphate, and 1,5-AG in a sample canbe detemined by measuring the amount of 1,5-AG-6-phosphate formed.

For the determination of 1,5-AG, after glucose ina sample is eliminatedby the above reaction, 1,5-AG-6-phosphate dehydrogenase is added to thesample in the presence of an oxidized coenzyme and a reaction is carriedout at 10-50° C. for 1-30 minutes, preferably 2-10 minutes, if necessaryin the presence of an aqueous medium, an enzyme activity moderator, anactivator, a preservative, a stabilizer, a surfactant, a chromogen, anelectron acceptor, a tetrazolium salt, an additional enzyme, a substratefor said enzyme, a coenzyme, etc. The concentration of 1,5-AG can bedetermined by directly determining the amount of the reduced coenzymeformed by the reaction, for example, by measuring the absorbance at 340nm, or by converting the reduced coenzyme into another substance andthen determining the amount of the substance.

Either the oxidized coenzyme or 1,5-AG-6-phosphate dehydrogenase used inthe determination of 1,5-AG may be present in the step of glucoseelimination, so far as it does not affect the reaction for eliminatingglucose.

As the NDP-dependent hexokinase, any enzyme can be used which catalyzesthe reaction for forming glucose-6-phosphate and NMP using glucose asthe substrate and consuming NDP and also catalyzes the reaction forforming 1,5-AG-6-phosphate and NMP using 1,5-AG as the substrate andconsuming NDP. Examples of suitable enzymes are the enzyme derived froma hyperthermophile, Pyrococcus furiosus DSM3638 (Japanese PublishedUnexamined Patent Application No. 234098/97) and the enzyme derived fromThermococcus litoralis (TLHK), which are acquirable from Asahi ChemicalIndustry Co., Ltd.

As the NTP-dependent hexokinase or NTP-dependent glucokinase, any enzymecan be used which catalyzes the reaction for forming glucose-6-phosphateand NDP using glucose as the substrate and consuming NTP and alsocatalyzes the reaction for forming 1,5-AG-6-phosphate and NDP using1,5-AG as the substrate and consuming NTP. Examples of suitable enzymesare the enzymes described above.

As the 1,5-AG-6-phosphate dehydrogenase, any enzyme can be used whichcatalyzes the reaction for forming a compound represented by C₆H₁₁O₈P₁and a reduced coenzyme from 1,5-AG-6-phosphate and an oxidized coenzyme.

An example of 1,5-AG-6-phosphate dehydrogenase which is the enzymecatalyzing the above reaction is the enzyme derived from Escherichiacoli DH1 (ATCC 33849). This enzyme can be prepared, for example,according to the method described in Japanese Published UnexaminedPatent Application No. 84953/98.

The concentration of 1,5-AG-6-phosphate dehydrogenase in the reactionmixture is preferably 0.5-100 U/ml, more preferably 1-50 U/ml, and mostpreferably 2-40 U/ml. The concentration of the oxidized coenzyme in thereaction mixture is preferably 0.1-100 mM, more preferably 1-50 mM, andmost preferably 2-20 mM.

The concentrations of NDP-dependent hexokinase, NTP-dependenthexokinase, NTP-dependent glucokinase, phosphohexose isomerase,6-phosphofructokinase, NDP and NTP in the reaction mixture are the sameas those described above for the reaction for glucose elimination.

Examples of the oxidized coenzyme include oxidized nicotinamide adeninedinucleotide (NAD), oxidized nicotinamide adenine dinucleotide phosphate(NADP), thio NAD and thio NADP.

Examples of NTP include adenosine triphosphate, guanosine triphosphate,cytidine triphosphate, thiamine triphosphate, uridine triphosphate andinosine triphosphate. Preferred is adenosine triphosphate.

Examples of NDP include adenosine diphosphate, guanosine diphosphate,cytidine diphosphate, thiamine diphosphate, uridine diphosphate andinosine diphosphate. Preferred is adenosine diphosphate.

The formed reduced coenzyme can be converted into another substance anddetermined with a high sensitivity. For example, as shown by thefollowing equation, the reduced coenzyme is acted on by an electronacceptor in the presence of a tetrazolium salt and the formed formazanpigment is calorimetrically determined.

Tetrazolium salts useful in this method include indonitro tetrazolium(INT), nitro blue tetrazolium (NBT),2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonyl)-2H-tetrazoliummonosodiumsalt (hereinafter referred to as WST-1),2-(4-iodophenyl)-3-(2,4-dinitrophenyl)-5-(2,4-disulfenyl)-2H-tetrazoliummonosodium salt (hereinafter referred to as WST-3),3,3′-[3,3′-dimethoxy-(1,1′-biphenyl)-4,4′-diyl]-bis[2-(4-nitrophenyl)-5-phenyl-2Htetrazolium chloride] (NTB) and3-(4,5-dimethylthiazole-2-phenyl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoliumsalt (MTS).

Tetrazolium salts which are used as chromogens can also be used. As thetetrazolium salt is used for the enhancement of sensitivity, thosehaving high molecular extinction coefficient are preferred. Further,considering that the method will be applied usually to clinical assays,those which are converted into water-soluble formazan pigments afterreduction are preferred. Specifically, WST-1 and WST-3 are preferablyused. The amount of the tetrazolium salt for clinical use is preferably0.01-50 mM.

The initial concentration of the tetrazolium salt in the reactionmixture is 0.01-50 mM, preferably 0.05-10 mM.

As the electron acceptor, phenazine methosulfate,1-methoxy-5-methylphenazine methosulfate, Meldola's Blue, diaphorase,etc. may be used. An example of the diaphorase is the enzyme derivedfrom Bacillus megaterium, which is acquirable from Asahi ChemicalIndustry Co., Ltd. and Toyobo Co., Ltd.

The initial concentration of the electron acceptor in the reactionmixture is 0.01-50 mM, preferably 0.05-10 mM.

The reaction is carried out at 10-50° C. for 1-30 minutes, preferably2-10 minutes. This reaction may be carried out after the completion ofthe above reaction for forming the reduced coenzyme, but is preferablycarried out simultaneously with the above reaction.

Described below is another method for determining the formed reducedcoenzyme via the conversion into another substance. In this method, asshown by the following equation, the reduced coenzyme is acted on byreduced coenzyme oxidase and peroxidase in the presence of a chromogenand the formed pigment is calorimetrically determined. As the chromogen,chromogens used in combination with 4-aminoantipyrine or the like may beused, but those which can be used alone to produce pigments arepreferred.

Examples of the chromogens which can be used alone arebis[3-bis(4-chlorophenyl)-methyl -4-dimethylaminophenyl]amine (BCMA),bis[3-bis(4-chlorophenyl)-methyl-4-carboxyethylaminophenyl]amine,10-N-methylcarbamoyl-3,7-dimethylamino-10H-phenothiazine (MCDP) and10-N-carboxymethylcarbamoyl-3,7-dimethylamino -10H-phenothiazine (CCAP).

Examples of the chromogens to be used in combination with4-aminoantipyrine are N-ethyl-N-(3-methylphenyl)-N′-succinylethylenediamine (EMSE), N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine (TOOS) and N,N-bis(4-sulfobutyl)-m-toluidine disodium salt.

The reaction is carried out at 10-50° C. for 1-30 minutes, preferably2-10 minutes. This reaction may be carried out after the completion ofthe above reaction for forming the reduced coenzyme, but is preferablycarried out simultaneously with the above reaction.

As the aqueous medium, water-containing liquids such as buffers andphysiological saline can be used. Buffers are preferably used.

Examples of the buffers are lactate buffer, citrate buffer, acetatebuffer, succinate buffer, phthalate buffer, phosphate buffer,triethanolamine buffer, diethanolamine buffer, lysine buffer, barbitalbuffer, tris(hydroxymethyl)aminomethane buffer, imidazole buffer, malatebuffer, oxalate buffer, glycine buffer, borate buffer, carbonate bufferand Good's buffer.

Examples of the enzyme activity moderators are metal chelating agentssuch as 1,10-phenanthroline, sugar alcohols such as mannitol andglycerol, metal ions such as magnesium, manganese, zinc and copper, andSH-blocking agents such as iodoacetic acid and iodoacetamide.

Examples of the enzyme stabilizers are metal chelating agents such asethylenediaminetetraacetic acid, polysaccharides such as soluble starchand derivatives thereof, proteins such as albumin and globulin,water-soluble high-molecular weight compounds such as polyethyleneglycol, and SH group-containing compounds such as phosphine andcysteine.

Examples of the surfactants are polyoxyethylene octylphenyl ether(Nonion HS-210, Kao Corporation), 3-[(3-chloramidepropyl)dimethylamino]propanesulfonic acid, Triton X-100 and sodium dodecyl sulfate.

An example of the preservatives is sodium azide.

As the additional enzyme, oxidized coenzyme oxidase, peroxidase, etc.can be used.

The reagent for the determination of 1,5-AG according to the presentinvention comprises (a) NDP, NTP, NDP-dependent hexokinase,phosphohexose isomerase, 6-phosphofructokinase, an oxidized coenzyme and1,5-AG-6-phosphate dehydrogenase, or (b) one member selected from thegroup consisting of NTP-dependent hexokinase and NTP-dependentglucokinase, NTP, phosphohexose isomerase, 6-phosphofructokinase, anoxidized coenzyme and 1,5-AG-6-phosphate dehydrogenase, and mayadditionally contain, if necessary, the above-mentioned buffer agent,enzyme activity moderator, activator, preservative, stabilizer,surfactant, chromogen, electron acceptor, tetrazolium salt, additionalenzyme, substrate for said enzyme, coenzyme, etc.

Said reagent can be a kit for the determination of 1,5-AG whichcomprises 1) the first reagent comprising (a) NDP, NTP, NDP-dependenthexokinase, phosphohexose isomerase and 6-phosphofructokinase, or (b)one member selected from the group consisting of NTP-dependenthexokinase and NTP-dependent glucokinase, NTP, phosphohexose isomeraseand 6-phosphofructokinase, and if necessary, the above-mentioned bufferagent, enzyme activity moderator, activator, preservative, stabilizer,surfactant, chromogen, electron acceptor, tetrazolium salt, additionalenzyme, substrate for said enzyme, coenzyme, etc., and 2) the secondreagent comprising 1,5-AG-6-phosphate dehydrogenase and an oxidizedcoenzyme, and if necessary, the above-mentioned buffer agent, enzymeactivity moderator, activator, preservative, stabilizer, surfactant,chromogen, electron acceptor, tetrazolium salt, additional enzyme,substrate for said enzyme, coenzyme, etc. It is also possible toformulate the second reagent to contain either one of the1,5-AG-6-phosphate dehydrogenase and the oxidized coenzyme and toformulate the first reagent to contain the other one.

The reagent for the elimination of glucose according to the presentinvention comprises NDP, NTP, NDP-dependent hexokinase, phosphohexoseisomerase and 6-phosphofructokinase, and if necessary, theabove-mentioned buffer agent, enzyme activity moderator, activator,preservative, stabilizer, surfactant, chromogen, electron acceptor,tetrazolium salt, additional enzyme, substrate for said enzyme,coenzyme, etc.

The reagent for the determination of an analyte according to the presentinvention comprises NDP, NTP, NDP-dependent hexokinase, phosphohexoseisomerase, 6-phosphofructokinase, and an enzyme acting on the analyte ora substance reacting with the analyte, and if necessary, theabove-mentioned buffer agent, enzyme activity moderator, activator,preservative, stabilizer, surfactant, chromogen, electron acceptor,tetrazolium salt, additional enzyme, substrate for said enzyme,coenzyme, etc.

Said reagent can be a kit which comprises 1) the first reagentcomprising NDP, NTP, NDP-dependent hexokinase, phosphohexose isomeraseand 6-phosphofructokinase, and if necessary, the above-mentioned bufferagent, enzyme activity moderator, activator, preservative, stabilizer,surfactant, chromogen, electron acceptor, tetrazolium salt, additionalenzyme, substrate for said enzyme, coenzyme, etc., and 2) the secondreagent comprising an enzyme acting on the analyte or a substancereacting with the analyte, and if necessary, the above-mentioned bufferagent, enzyme activity moderator, activator, preservative, stabilizer,surfactant, chromogen, electron acceptor, tetrazolium salt, additionalenzyme, substrate for said enzyme, coenzyme, etc.

Each of the reagents according to the present invention may be providedin the form of a freeze-dried preparation or in the form of a solutionin an aqueous medium such as water.

Certain embodiments of the present invention are illustrated in thefollowing examples.

EXAMPLE 1

A reagent for the elimination of glucose having the followingcomposition was prepared.

Tris-HCl buffer (pH 8.0) 50 mM Magnesium chloride 1 mg/ml ADP-dependenthexokinase (derived from 10 U/ml Thermococcus litoralis, Asahi ChemicalIndustry Co., Ltd.) Phosphohexose isomerase (derived from Bacillus 40U/ml stearothermophilus, Unitika Ltd.) 6-Phosphofructokinase (derivedfrom Bacillus 30 U/ml stearothermophilus, Unitika Ltd.) ADP (OrientalYeast Co., Ltd.) 3 mM ATP (Sigma Chemical Co.) 10 mM

EXAMPLE 2

Reagents for the determination of 1,5-AG having the followingcomposition were prepared.

Reagent 1 Tris-HCl buffer (pH 8.5) 50 mM Magnesium chloride 1 mg/ml NADP(Sigma Chemical Co.) 4 mM ADP (Oriental Yeast Co., Ltd.) 3 mM ATP (SigmaChemical Co.) 10 mM Phosphohexose isomerase (derived from Bacillus 40U/ml stearothermophilus, Unitika Ltd.) 6-Phosphofructokinase (derivedfrom Bacillus 30 U/ml stearothermophilus, Unitika Ltd.) Diaphorase(derived from Bacillus megaterium, 10 U/ml Asahi Chemical Industry Co.,Ltd.) ADP-dependent hexokinase (derived from 10 U/ml Thermococcuslitoralis, Asahi Chemical Industry Co., Ltd.) Reagent 2 Glycine-NaOHbuffer (pH 10.0) 200 mM WST-1 (Dojindo Laboratories) 0.5 mM1,5-AG-6-phosphate dehydrogenase (derived from 20 U/ml E. coli DH1 (ATCC33949), Asahi Chemical Industry Co., Ltd.)

EXAMPLE 3

A standard solution of 1,5-AG (25 μg/ml) was diluted to prepare fivesolutions having different concentrations. To 0.075 ml of each of thesolutions and purified water was added 2.25 ml of reagent 1 prepared inExample 2, followed by incubation at 37° C. for 5 minutes. After 0.75 mlof reagent 2 prepared in Example 2 was added to each mixture, thereaction was carried out for 5 minutes and the absorbance was measuredat 438 nm. The obtained calibration curve is shown in FIG. 1.

EXAMPLE 4

The following experiment on glucose elimination was carried out to provethe utility of the method according to the invention. Reagent 1 preparedin Example 2 was poured into test tubes in 2.25 ml portions. To the testtubes were respectively added 0.075 ml each of (a) purified water, (b) atest solution containing 25 μg/ml 1,5-AG, (c) a test solution containing2000 mg/dl glucose, and (d) a test solution containing 25 μg/ml 1,5-AGand 2000 mg/dl glucose, followed by incubation at 37° C. for 5 minutes.After 0.75 ml of reagent 2 prepared in Example 2 was added to eachmixture, the reaction was carried out for5minutesandtheabsorbancewasmeasuredat438nm. Theresults are shown inTable 1.

TABLE 1 Test solution Measurement result (a) Purified water (blank)0.096 Abs (b) 1,5-AG 25 μg/ml 0.230 Abs (c) Glucose 2000 mg/dl 0.096 Abs(d) 1,5-AG + glucose 0.226 Abs

As shown in Table 1, the value of (c) exactly agreed with that of (a),indicating that 2000 mg/dl glucose contained in test solution (c) wascompletely eliminated by the method of the invention. Further, the valueof (b) closely agreed with that of (d). The utility of the methodaccording to the invention was thus proved.

EXAMPLE 5

Determination of 1,5-AG was carried out on 50 serum samples to examinethe correlation between the method according to the invention and aknown method.

(a) To 2.25 ml of reagent 1 prepared in Example 2 was added 0.075 ml ofeach sample, followed by incubation at 37° C for 5 minutes. After 0.75ml of reagent 2 prepared in Example 2 was added to the mixture, thereaction was carried out for 5 minutes and the absorbance was measuredat 438 nm. The 1,5-AG concentration in the sample was calculated fromthe absorbance according to the equation obtained from the calibrationcurve of Example 1 shown in FIG. 1.

(b) Measurement was made on the 50 serum samples using an approvedreagent for in vitro diagnostic use, Lana 1,5-AGAutoII (Nippon KayakuCo., Ltd., Approval No. (08AM) 0112) according to its “measurementprocedure” and the 1,5-AG concentration was calculated according to its“method of calculating 1,5-AG concentration”.

The 1,5-AG concentration determined in (a) was plotted as ordinate andthat determined in (b) as abscissa. The result is shown in FIG. 2.

The result in FIG. 2 shows a good correlation between the data with thecorrelation coefficient r=0.9966 and the regression equationy=0.9839×+0.0576.

EXAMPLE 6

Reagents were prepared in the same manner as in Example 2, except thatthe ADP concentration in the first reagent was varied as indicated inTable 2 and Triton X-100 was added to the composition of reagent 2 at aconcentration of 0.4%.

Test solutions containing 25 μg/ml 1,5-AG and glucose at theconcentrations indicated in Table 2 were prepared.

Determination of 1,5-AG was carried out on the test solutions in thesame manner as in Example 3. The results are shown in Table 2.

TABLE 2 Glucose concentration ADP concentration (mM) (mg/dl) 0.5 1 2 3 45 6 10 0 25.2 25.1 25.0 25.0 25.2 25.1 25.1 25.0 400 25.0 25.1 25.1 25.025.1 25.1 25.1 25.0 800 24.9 25.2 25.0 25.0 25.2 25.0 25.1 25.1 120024.8 25.0 24.9 25.1 25.1 25.1 25.3 25.2 1600 24.8 25.0 24.8 25.0 25.125.2 25.2 25.3 2000 24.8 25.1 25.0 25.1 25.2 25.3 25.3 25.6

It was demonstrated that 1,5-AG in samples can be accurately determinedby employing the above method for glucose elimination usingADP-dependent hexokinase, regardless of ADP concentration in thereagents and glucose concentration in the samples.

EXAMPLE 7

Reagents for the determination of 1,5-AG having the followingcomposition were prepared.

Reagent 1 Tris-HCl buffer (pH 8.0) 50 mM Magnesium chloride 1 mg/ml NADP(Sigma Chemical Co.) 4 mM ATP (Sigma Chemical Co.) 10 mM Phosphohexoseisomerase (derived from Bacillus 40 U/ml stearothermophilus, UnitikaLtd.) 6-Phosphofructokinase (derived from Bacillus 30 U/mlstearothermophilus, Unitika Ltd.) Diaphorase (derived from Bacillusmegaterium, 10 U/ml Asahi Chemical Industry Co., Ltd.) ATP-dependenthexokinase (derived from yeast, 100 U/ml Oriental Yeast Co., Ltd.)Reagent 2 Glycine-NaOH buffer (pH 10.0) 200 mM WST-1 (DojindoLaboratories) 0.5 mM 1,5-AG-6-phosphate dehydrogenase (derived from 20U/ml E. coli DH1 (ATCC 33849), Asahi Chemical Industry Co., Ltd.)

EXAMPLE 8

Standard solutions respectively containing 50, 100, 150, 200 and 250μg/ml 1,5-AG were prepared. To 0.075 ml of each of the standardsolutions and purified water was added 2.25 ml of reagent 1 prepared inExample 7, followed by incubation at 37° C. for 5 minutes. After 0.75 mlof reagent 2 prepared in Example 7 was added to each mixture, thereaction was carried out for 5 minutes and the absorbance was measuredat 438 nm. The obtained calibration curve is shown in FIG. 3.

EXAMPLE 9

The following experiment on glucose elimination was carried out to provethe utility of the method according to the invention. Reagent 1 preparedin Example 7 was poured into test tubes in 2.25 ml portions. To the testtubes were respectively added 0.075 ml each of (a) purified water, (b) atest solution containing 250 μg/ml 1,5-AG, (c) a test solutioncontaining 100 mg/dl glucose, and (d) a test solution containing 250μg/ml 1,5-AG and 100 mg/dl glucose, followed by incubation at 37° C. for5 minutes. After 0.75 ml of reagent 2 prepared in Example 7 was added toeach mixture, the reaction was carried out for 5minutes and theabsorbance was measured at 438 nm. The results are shown in Table 3.

TABLE 3 Test solution Measurement result (a) Purified water (blank)0.280 Abs (b) 1,5-AG 250 ug/ml 0.440 Abs (c) Glucose 100 mg/dl 0.279 Abs(d) 1,5-AG + glucose 0.441 Abs

As shown in Table 3, the value of (c) closely agreed with that of (a),indicating that 100 mg/dl glucose contained in test solution (c) wascompletely eliminated by the method of the invention. Further, the valueof (b) closely agreed with that of (d). The utility of the methodaccording to the invention was thus proved.

What is claimed is:
 1. A method for determining 1,5-anhydroglucitol in asample containing glucose, which comprises: contacting the sample withadenosine diphosphate, adenosine triphosphate, adenosinediphosphate-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase to form fructose-1,6-diphosphate and1,5-anhydroglucitol-6-phosphate; dehydrogenating the1,5-anhydroglucitol-6-phosphate by the action of1,5-anhydroglucitol-6-phosphate dehydrogenase in the presence of anoxidized coenzyme; and measuring the amount of reduced coenzyme formedby the dehydrogenation reaction.
 2. The method according to claim 1,wherein said coenzyme is nicotinamide adenine dinucleotide phosphate. 3.The method according to claim 1 or 2, wherein said measurement of theamount of the reduced coenzyme is carried out by colorimetry of apigment formed from a tetrazolium salt.
 4. A reagent for thedetermination of 1,5-anhydroglucitol, comprising adenosine diphosphate,adenosine triphosphate, adenosine diphosphate-dependent hexokinase,phosphohexose isomerase, 6-phosphofructokinase, an oxidized coenzyme and1,5-anhydroglucitol-6-phosphate dehydrogenase.
 5. The reagent accordingto claim 4, wherein said coenzyme is nicotinamide adenine dinucleotidephosphate.
 6. The reagent according to claim 4 or 5, further comprisinga tetrazolium salt and an electron acceptor.
 7. A reagent kit for thedetermination of 1,5-anhydrogluitol, said reagent kit comprising (i) areagent comprising adenosine diphosphate, adenosine triphosphate,adenosine diphosphate-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase and (ii) a second reagent comprising oxidizednicotinamide adenine dinucleotide phosphate and1,5-anhydroglucitol-6-phosphate dehydrogenase.
 8. A method foreliminating glucose in a sample, which comprises converting glucose inthe sample into fructose-1,6-diphosphate by the action of adenosinediphosphate-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase in the presence of adenosine diphosphate andadenosine triphosphate.
 9. A reagent for the elimination of glucose,comprising adenosine diphosphate, adenosine triphosphate, adenosinediphosphate-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase.
 10. A method for determining an analyte in asample containing glucose, which comprises: converting glucose in thesample into fructose-1,6-diphosphate by the action of adenosinediphosphate-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase in the presence of adenosine diphosphate,adenosine triphosphate; and determining the analyte in the sample byusing a chemical or enzymatic reaction.
 11. A reagent for thedetermination of an analyte, comprising adenosine diphosphate, adenosinetriphosphate, adenosine diphosphate-dependent hexokinase, phosphohexoseisomerase and 6-phosphofructokinase, and an enzyme acting on the analyteor a substance reacting with the analyte.
 12. A reagent kit for thedetermination of an analyte, comprising (i) a reagent comprisingadenosine diphosphate, adenosine triphosphate, adenosinediphosphate-dependent hexokinase, phosphohexose isomerase and6-phosphofructokinase, and (ii) a second reagent comprising an enzymeacting on the analyte or a substance reacting with the analyte.
 13. Areagent kit for the determination of 1,5-AG, comprising: a first reagentcomprising (a) NDP, NTP, NDP-dependent hexokinase, phosphohexoseisomerase and 6-phosphofructokinase, and (b) an oxidized coenzyme; and asecond reagent comprising 1,5-AG-6-phosphate dehydrogenase.
 14. Thereagent kit according to claim 13, wherein said NDP, NTP, NDP-dependenthexokinase are ADP, ATP, and ADP-dependent hexokinase, respectively. 15.The reagent kit according to claim 13 or 14, wherein said first reagentfurther comprises an electron carrier and magnesium salt, and saidsecond reagent further comprises tetrazolium salt.
 16. A reagent kit forthe determination of 1,5-AG, comprising: a first reagent comprising (a)one member selected from the group consisting of NTP-dependenthexokinase and NTP-dependent glucokinase, NTP, phosphohexose isomeraseand 6-phosphofrutokinase, and (b) an oxidized coenzyme; and a secondreagent comprising 1,5-AG-6-phosphate dehydrogenase.
 17. The reagent kitaccording to claim 16, wherein said NTP-dependent hexokinase andNTP-dependent glucokinase are ATP-dependent hexokinase and ATP-dependentglucokinase, respectively.
 18. The reagent kit according to claim 16 or17, wherein said first reagent further comprises an electron carrier andmagnesium salt, and said second reagent further comprises tetrazoliumsalt.